NewEdge Advisors LLC Acquires 5,958 Shares of Sanofi (NASDAQ:SNY)

NewEdge Advisors LLC boosted its holdings in Sanofi (NASDAQ:SNY) by 19.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 36,796 shares of the company’s stock after purchasing an additional 5,958 shares during the period. NewEdge Advisors LLC’s holdings in Sanofi were worth $1,775,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in SNY. Abel Hall LLC lifted its stake in shares of Sanofi by 1.8% in the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after acquiring an additional 194 shares during the last quarter. Providence Capital Advisors LLC lifted its position in Sanofi by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock valued at $2,653,000 after purchasing an additional 201 shares during the last quarter. Keudell Morrison Wealth Management boosted its stake in shares of Sanofi by 1.7% during the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after purchasing an additional 217 shares during the period. Bailard Inc. grew its holdings in shares of Sanofi by 1.4% in the fourth quarter. Bailard Inc. now owns 16,359 shares of the company’s stock worth $789,000 after purchasing an additional 220 shares during the last quarter. Finally, Old Port Advisors increased its stake in shares of Sanofi by 0.6% in the fourth quarter. Old Port Advisors now owns 36,704 shares of the company’s stock worth $1,770,000 after buying an additional 232 shares during the period. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $51.85 on Wednesday. Sanofi has a 1 year low of $45.80 and a 1 year high of $60.12. The stock has a market capitalization of $130.99 billion, a P/E ratio of 20.82, a P/E/G ratio of 1.01 and a beta of 0.57. The company’s 50-day moving average is $54.61 and its 200 day moving average is $52.11. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be issued a dividend of $2.0369 per share. This represents a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.48. Sanofi’s payout ratio is 64.26%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. BNP Paribas initiated coverage on Sanofi in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 target price on the stock. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, The Goldman Sachs Group started coverage on Sanofi in a research note on Friday, March 21st. They set a “neutral” rating and a $65.00 target price on the stock. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $63.33.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.